



**Biomedical Research
and Training Institute**

BIOMEDICAL RESEARCH AND TRAINING INSTITUTE

A Non-Profit Organization Promoting Health
Research for Development in Southern Africa

10 Seagrave Road
Cnr S. Nujoma St & Seagrave Rd
Avondale
Harare
P.O. Box CY 1753
Causeway, Harare, Zimbabwe
Tel: +263 4 336691 / 335641 / 333091
Fax: +263 4 333464
E-mail: admin@brti.co.zw
Website: <http://www.brti.co.z>

Dr. Henning Gädeke, Chair of the EDCTP Association Board and the Global Health EDCTP3

C/O Dr. Michael Makanga, Executive Director of the Global Health EDCTP3 Joint Undertaking Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

22 August 2025

Ref: Letter of endorsement

Dear Sir/Madam,

On behalf of Biomedical Research and Training Institute (BRTI), 10 Seagrave Road, Avondale, Harare, Zimbabwe and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

The Biomedical Research and Training Institute (BRTI) is a non-profit making private organization registered in Zimbabwe (registration number 1676/95). BRTI is again registered with the Health Profession Authority (HPA) of Zimbabwe. Its mandate is to support health research and the training of professionals in biomedical research in Southern Africa, through the management of research projects and the training of health professionals in the areas of: Social and Behavioural Sciences Research; Biomedical Research; Epidemiological Research; Public Health and Veterinary Research. The mission of the BRTI is to promote the health and quality of life of the peoples of Africa through research and training in the field of biomedicine.

BRTI partners and collaborates with Zimbabwean government, universities, industry and various scientific disciplines in strengthening and enhancing research capacity and its outcomes while fostering local ownership, sustainable health systems and research infrastructures in Zimbabwe and the region. BRTI prioritizes research on infectious diseases that disproportionately affect LMICs, such as HIV/AIDS, tuberculosis, malaria, neglected tropical diseases and it is responsive to emerging and re-emerging health challenges and changing global priorities. BRTI values equity and inclusiveness in all its activities ensuring that new interventions are accessible to populations while promoting inclusive participation from diverse regions and communities in its research and decision-making processes.

BRTI upholds scientific excellence where high-quality research which embrace innovative and high-quality clinical trials that adhere to international standards and ethical principles in research, to ensure safety and rights of participants is practiced. It also facilitates the translation of scientific research into practical applications for disease prevention and treatment. The institution maintains transparency in all its decision-making and grant management processes through open communication and robust mechanisms of for assessing the impact and effectiveness of funded projects.

As a participating site, BRTI will contribute to the objectives of the EDCTP3 JU for the duration of the project through provision of governance services (Board fees and expenses), expert personnel, laboratory and diagnostic infrastructure, biorepository facilities, quality management services, financial and administrative oversight, continued mentorship and training for research and clinical scientists, provision of a digital platform for communication and dissemination. All these add value to the sustainability of running a successful implementing the project and we are committed to providing the above throughout the duration of the and beyond.

BRTI will work with the work package leaders to ensure the following activities are funded:

WP	Activities	Deliverables	Entities to be funded
WP1	Signing of award agreements	Signed Awards	-
WP2	Financial Reporting	Financial Reports submitted	-
	Technical Reporting	Technical reports submitted	-
	General Assembly meetings	GA meetings done	Participants
	Project Kick-off meetings	Meeting Minutes	Participants
	Scientific days	Scientific days done	Participants
WP3	Vaccine/drug hesitancy and health literacy	Training report	Training costs
	Precision Drone Pilot Training	6 Trained Drone Pilots	Training costs
	Antimicrobial Resistance & Drug Stewardship Training	20 Trained AMR Scientists	Training costs
	Regional Innovation challenges	Challenge completed	Workshop costs
	2 persons to attend science to policy training at CAPRISA	Training report	Participants
	1 person to attend Grant Writing Workshop at CAPRISA/BHP	Training report	Participants
	3 persons to attend regional cross-border HIV Management Protocol engagement meeting.	Training report	Participants
WP2-WP6	PhD fellowship (36 months) - Social and behavioural Sciences.	1 PhD Certification	Fellow
WP2-WP6	PhD fellowship (36 months) - Epidemiology/AMR	1 PhD Certification	Fellow
	1 person to attend regional Genomics Training /Workshop at CISM		Workshop costs
WP4	Regional Symposium with Biotech and Pharma companies for 2 days	Symposium successfully hosted	Workshop costs
	Biobank facility refurbishments and partitioning.	Refurbished Biobank and established Data Centre	Infrastructure
	Drone use feasibility study	Feasibility report	Feasibility study
WP5	Data Centre establishment	Data centre established	Infrastructure
WP6	2 people to attend EDCTP forum attendance	Attendance report	Participants
	1 person to attend clinical trial site management and operations training - UCTLI	Training report	Participant
	2 persons to attend World TB conferences	Attendance report	Participants
	1 person to attend AMR annual conferences	Attendance report	Participant
	2 persons to attend National conferences	Attendance report	Participants

We estimate the total value of this contribution to be EUR € 61,666.82.

Cost Category	Total In Kind Contribution	Year 1	Year 2	Year 2	Year 2	Year 2	TOTAL IN KIND CONTRIBUTION
Board fees and expenses	€4,070.47	€814.09	€814.09	€814.09	€ 814.10	€ 814.10	€ 4,070.47
Quality systems management	€7,606.60	€ 1,521.32	€ 1,521.32	€1,521.32	€1,521.32	€1,521.32	€ 7,606.60
Oversight - Management, Financial and HR Services	€25,910.40	€5,182.08	€ 5,182.08	€5,182.08	€ 5,182.08	€ 5,182.08	€ 25,910.40
Laboratory & Biobank Infrastructure (Building and equipment)	€20,728.32	€4,145.66	€4,145.66	€4,145.66	€4,145.67	€4,145.67	€20,728.32
Officers and Directors Liability	€600.74	€120.15	€120.15	€120.15	€120.15	€120.14	€ 600.74
Professional indemnity cover	€1,202.25	€240.45	€240.45	€240.45	€240.45	€240.45	€ 1,202.25
Systems subscriptions (Payroll and Pastel)	€1,548.04	€309.61	€309.61	€309.61	€309.61	€309.60	€1,548.04
TOTAL	€ 61,666.82	€ 12,333.36	€ 12,333.36	€ 12,333.36	€ 12,333.38	€ 12,333.36	€ 61,666.82

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text



Yours faithfully,

Dr. J. Mutsvangwa, PhD (Med Microbiology)
 Senior Clinical Research Scientist
 Principal Investigator (PI): ERASE-TB, TESA III, TAGENDI, XACT III, XACT 19 and EPI-TB
 Director, Molecular Laboratory
 M&E Specialist: Global TB/HIV programs